DE69703121D1 - Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit - Google Patents
Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheitInfo
- Publication number
- DE69703121D1 DE69703121D1 DE69703121T DE69703121T DE69703121D1 DE 69703121 D1 DE69703121 D1 DE 69703121D1 DE 69703121 T DE69703121 T DE 69703121T DE 69703121 T DE69703121 T DE 69703121T DE 69703121 D1 DE69703121 D1 DE 69703121D1
- Authority
- DE
- Germany
- Prior art keywords
- compositions
- methods
- mammalia
- alpha
- prevent inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 title abstract 5
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 206010061218 Inflammation Diseases 0.000 title 1
- 241000124008 Mammalia Species 0.000 title 1
- 230000033115 angiogenesis Effects 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2787196P | 1996-10-25 | 1996-10-25 | |
PCT/US1997/019772 WO1998017796A2 (en) | 1996-10-25 | 1997-10-24 | Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian cd97 alpha subunit |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69703121D1 true DE69703121D1 (de) | 2000-10-19 |
Family
ID=21840250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69703121T Expired - Lifetime DE69703121D1 (de) | 1996-10-25 | 1997-10-24 | Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit |
Country Status (8)
Country | Link |
---|---|
US (2) | US6365712B1 (de) |
EP (1) | EP0938557B1 (de) |
JP (1) | JP2001510987A (de) |
AT (1) | ATE196314T1 (de) |
AU (1) | AU5158098A (de) |
CA (1) | CA2270154A1 (de) |
DE (1) | DE69703121D1 (de) |
WO (1) | WO1998017796A2 (de) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU768859B2 (en) * | 1999-07-29 | 2004-01-08 | Dyax Corp. | Binding moieties for fibrin |
US20070055367A1 (en) * | 2000-03-15 | 2007-03-08 | Orbus Medical Technologies, Inc. | Medical device with coating that promotes endothelial cell adherence and differentiation |
US20030229393A1 (en) * | 2001-03-15 | 2003-12-11 | Kutryk Michael J. B. | Medical device with coating that promotes cell adherence and differentiation |
CN100506293C (zh) | 2000-03-15 | 2009-07-01 | 祥丰医疗有限公司 | 促进内皮细胞粘附的涂层 |
US20070141107A1 (en) * | 2000-03-15 | 2007-06-21 | Orbusneich Medical, Inc. | Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device |
US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
US8460367B2 (en) * | 2000-03-15 | 2013-06-11 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
GB0009181D0 (en) * | 2000-04-13 | 2000-05-31 | Isis Innovation | Protein |
GB2367822A (en) * | 2000-06-19 | 2002-04-17 | Smithkline Beecham Corp | CD97 polypeptides |
US6984373B2 (en) | 2000-12-23 | 2006-01-10 | Dyax Corp. | Fibrin binding moieties useful as imaging agents |
AU2002252175A1 (en) | 2001-03-02 | 2002-09-19 | The Brigham And Women's Hospital | Lipoxin analogs as novel inhibitors of angiogenesis |
US8722654B2 (en) | 2001-03-02 | 2014-05-13 | The Brigham And Women's Hospital, Inc. | Lipoxin analogs as novel inhibitors of angiogenesis |
AU2003201573B2 (en) * | 2002-01-22 | 2009-02-26 | Biomatera Inc. | Method of drying biodegradable polymers |
KR20070008714A (ko) * | 2004-04-30 | 2007-01-17 | 오르버스네이치 메디칼 인코포레이티드 | 유전적으로-변형된 세포 포획용 코팅을 갖는 의료 장치 및이의 사용 방법 |
US7727718B2 (en) * | 2005-01-04 | 2010-06-01 | Molecular Research Center, Inc. | Reagents for storage and preparation of samples for DNA analysis |
WO2007084500A2 (en) * | 2006-01-13 | 2007-07-26 | Advanced Bionutrition Corporation | Continuous spray-capture production system |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
EP2537929B1 (de) | 2010-02-17 | 2017-04-12 | Japan Tobacco, Inc. | Regulierungsfaktor für pflanzenkomponenten und verwendung davon |
PL3013318T3 (pl) | 2013-06-28 | 2018-03-30 | Amgen Inc. | Stabilny ciekły preparat związku amg 416 (welkalcetyd) |
ES2939760T3 (es) | 2014-03-15 | 2023-04-26 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico para antígenos |
JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のmTOR阻害剤とCARの組み合わせ |
WO2016090034A2 (en) | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
US20180298068A1 (en) | 2015-04-23 | 2018-10-18 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
JP7118887B2 (ja) | 2015-11-23 | 2022-08-16 | ノバルティス アーゲー | 最適化されたレンチウイルス移入ベクターおよびその使用 |
RU2018127657A (ru) | 2015-12-30 | 2020-01-31 | Новартис Аг | Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью |
SG11201807489PA (en) | 2016-03-04 | 2018-09-27 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
EP3432924A1 (de) | 2016-03-23 | 2019-01-30 | Novartis AG | Zellsekretierte minikörper und verwendungen davon |
WO2017181119A2 (en) | 2016-04-15 | 2017-10-19 | Novartis Ag | Compositions and methods for selective protein expression |
US20190161542A1 (en) | 2016-08-01 | 2019-05-30 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
US20190375815A1 (en) | 2017-01-31 | 2019-12-12 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
CN111629749A (zh) | 2017-10-18 | 2020-09-04 | 诺华股份有限公司 | 用于选择性蛋白质降解的组合物和方法 |
RU2020116579A (ru) | 2017-10-25 | 2021-11-25 | Новартис Аг | Способы получения клеток, экспрессирующих химерный антигенный рецептор |
US20210040205A1 (en) | 2017-10-25 | 2021-02-11 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
EP3788369A1 (de) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarker zur auswertung von car-t-zellen zur vorhersage des klinischen ergebnisses |
EP3801769A1 (de) | 2018-05-25 | 2021-04-14 | Novartis AG | Kombinationstherapie mit therapien mit chimärem antigen-rezeptor (car) |
EP3802825A1 (de) | 2018-06-08 | 2021-04-14 | Intellia Therapeutics, Inc. | Zusammensetzungen und verfahren zur immunonkologie |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
BR112021011874A2 (pt) | 2018-12-20 | 2021-09-08 | Novartis Ag | Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona |
KR20210129672A (ko) | 2019-02-15 | 2021-10-28 | 노파르티스 아게 | 치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도 |
MX2021009763A (es) | 2019-02-15 | 2021-09-08 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. |
EP3959320A1 (de) | 2019-04-24 | 2022-03-02 | Novartis AG | Zusammensetzungen und verfahren für selektiven proteinabbau |
CN110627903B (zh) * | 2019-10-29 | 2021-09-21 | 河南大学 | 抗cd97单克隆抗体、其可变区与恒定区序列及应用 |
CA3165399A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
IL298473A (en) | 2020-06-11 | 2023-01-01 | Novartis Ag | zbtb32 inhibitors and uses thereof |
BR112022026202A2 (pt) | 2020-06-23 | 2023-01-17 | Novartis Ag | Regime de dosagem compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona |
CN116134027A (zh) | 2020-08-03 | 2023-05-16 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
WO2022229853A1 (en) | 2021-04-27 | 2022-11-03 | Novartis Ag | Viral vector production system |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2260797T3 (es) * | 1996-08-09 | 2006-11-01 | Stichting Sanquin Bloedvoorziening | Metodos y medios para modificar la activacion del complemento. |
-
1997
- 1997-10-24 WO PCT/US1997/019772 patent/WO1998017796A2/en active IP Right Grant
- 1997-10-24 AT AT97946405T patent/ATE196314T1/de not_active IP Right Cessation
- 1997-10-24 US US09/284,819 patent/US6365712B1/en not_active Expired - Fee Related
- 1997-10-24 AU AU51580/98A patent/AU5158098A/en not_active Abandoned
- 1997-10-24 JP JP51974798A patent/JP2001510987A/ja active Pending
- 1997-10-24 DE DE69703121T patent/DE69703121D1/de not_active Expired - Lifetime
- 1997-10-24 EP EP97946405A patent/EP0938557B1/de not_active Expired - Lifetime
- 1997-10-24 CA CA002270154A patent/CA2270154A1/en not_active Abandoned
-
2002
- 2002-01-29 US US10/059,506 patent/US6846911B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO1998017796A3 (en) | 1998-07-09 |
JP2001510987A (ja) | 2001-08-07 |
EP0938557B1 (de) | 2000-09-13 |
ATE196314T1 (de) | 2000-09-15 |
AU5158098A (en) | 1998-05-15 |
US6846911B2 (en) | 2005-01-25 |
US6365712B1 (en) | 2002-04-02 |
EP0938557A2 (de) | 1999-09-01 |
US20020168361A1 (en) | 2002-11-14 |
CA2270154A1 (en) | 1998-04-30 |
WO1998017796A2 (en) | 1998-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69703121D1 (de) | Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit | |
TR200000913T2 (tr) | Tıbbi maddeler | |
CY1117387T1 (el) | ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ | |
BR0008161A (pt) | Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral | |
ATE348157T1 (de) | Menschliche toll-ähnliche rezeptorproteine, zugehörige reagenzien und verfahren | |
BR9707819A (pt) | Imunogenos peptidicos | |
TR200301846T2 (tr) | Cripto bloke edici Antikorlar ve bu antikorların kullanımları. | |
ATE209207T1 (de) | Androgen rezeptor modulator verbindungen und verfahren | |
DE69636487D1 (de) | Zusammensetzungen zur Immuntherapie und Diagnose von Tuberculosis | |
CY1112055T1 (el) | Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα | |
DE69900468D1 (de) | Löslicher t-zell rezeptor | |
DK0845998T3 (da) | Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles | |
EE9900146A (et) | Lahustuvad lümfotoksiin-ß retseptorid, lümfotoksiini retseptori vastased antikehad ja lümfotoksiini ligandi vastased antikehad terapeutiliste agensitena immunoloogiliste haiguste raviks | |
PE20010516A1 (es) | Peptidos ciclicos con afinidad mejorada por los receptores de somatostatina | |
AU2003288810A1 (en) | Peptides that bind to the heparin binding domian of vegf and vegfr-2 | |
BR0114977A (pt) | segmentos preferidos de proteìna de filamento neural e métodos para uso dos mesmos | |
MXPA02005236A (es) | Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos. | |
DK1039931T3 (da) | Multivalente rekombinante antistoffer til at behandle HRV infektioner | |
ATE364180T1 (de) | Screeningverfahren mit bnpi und dnpi | |
NO984522L (no) | Monoklonale antistoffer som binder humant veksthormon (hGH) | |
TH57766B (th) | รีคอมไบแนนท์แอนติ-ไอดิโอไทพิคแอนติบอดี้ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8332 | No legal effect for de |